NO20055367L - Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst - Google Patents

Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst

Info

Publication number: NO20055367L
Authority: NO; Norway
Prior art keywords: phenyl; methyl; combinations; anxiety; piperazine
Prior art date: 2003-04-17

Application number

NO20055367A

Other languages

English (en)

Norwegian (no)

Inventor

Mauro Corsi

Sergio Melotto

Renzo Carletti

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-17

Filing date

2005-11-14

Publication date

2005-11-14

2005-11-14 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2005-11-14 Publication of NO20055367L publication Critical patent/NO20055367L/no

Links

AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title abstract 2
208000019901 Anxiety disease Diseases 0.000 title abstract 2
208000020401 Depressive disease Diseases 0.000 title abstract 2
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title abstract 2
230000036506 anxiety Effects 0.000 title abstract 2
229960002296 paroxetine Drugs 0.000 title abstract 2
MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 2
239000012453 solvate Substances 0.000 abstract 2
-1 4-fluoro-2-methylphenyl Chemical group 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

NO20055367A 2003-04-17 2005-11-14 Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst NO20055367L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0308968.7A GB0308968D0 (en)	2003-04-17	2003-04-17	Medicaments
PCT/EP2004/004126 WO2004091624A1 (fr)	2003-04-17	2004-04-16	Combinaison comprenant paroxetine et 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete

Publications (1)

Publication Number	Publication Date
NO20055367L true NO20055367L (no)	2005-11-14

Family

ID=9956996

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20055367A NO20055367L (no)	2003-04-17	2005-11-14	Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst
NO20055368A NO20055368L (no)	2003-04-17	2005-11-14	Kombinasjoner av paroksetin og 4-(S)-(4-acetyl-piperazin-1-yl-)-2-(R)-(4-trifluor-2-metyl-fenyl)-piperidin-1-karboksylsyre{1\\[1-(R)-3,5-bis-trifluormetyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20055368A NO20055368L (no)	2003-04-17	2005-11-14	Kombinasjoner av paroksetin og 4-(S)-(4-acetyl-piperazin-1-yl-)-2-(R)-(4-trifluor-2-metyl-fenyl)-piperidin-1-karboksylsyre{1\\[1-(R)-3,5-bis-trifluormetyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst

Country Status (18)

Country	Link
US (4)	US20060287325A1 (fr)
EP (4)	EP1613325A1 (fr)
JP (4)	JP2006523650A (fr)
KR (2)	KR20060003875A (fr)
CN (2)	CN1809355A (fr)
AU (2)	AU2004229181A1 (fr)
BR (2)	BRPI0409377A (fr)
CA (2)	CA2522311A1 (fr)
CO (1)	CO5700753A2 (fr)
GB (1)	GB0308968D0 (fr)
IS (2)	IS8129A (fr)
MA (2)	MA27730A1 (fr)
MX (2)	MXPA05011064A (fr)
NO (2)	NO20055367L (fr)
PL (2)	PL377857A1 (fr)
RU (2)	RU2005135649A (fr)
WO (4)	WO2004091616A1 (fr)
ZA (2)	ZA200508067B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0203020D0 (en) *	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
GB0403149D0 (en) *	2004-02-12	2004-03-17	Glaxo Group Ltd	Medicament
GB0409098D0 (en) *	2004-04-23	2004-05-26	Glaxo Group Ltd	Medicament
GB0426942D0 (en) *	2004-12-08	2005-01-12	Glaxo Group Ltd	Medicament
WO2007012968A2 (fr) *	2005-07-29	2007-02-01	Aurobindo Pharma Ltd	Forme dosifee stable d'un antidepresseur
GB0621229D0 (en) *	2006-10-20	2006-12-06	Glaxo Group Ltd	Novel use
CA2676357A1 (fr)	2007-01-24	2008-07-31	Glaxo Group Limited	Nouvelles compositions pharmaceutiques
WO2012175434A1 (fr) *	2011-06-20	2012-12-27	Glaxo Group Limited	Formulations pharmaceutiques comprenant du vestipitant
CN103446066B (zh) *	2013-09-16	2014-12-24	南通丝乡丝绸有限公司	帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL111002A (en) *	1993-09-22	1998-09-24	Glaxo Group Ltd	History of piperidine, their preparation and the pharmaceutical preparations containing them
US6117855A (en) *	1996-10-07	2000-09-12	Merck Sharp & Dohme Ltd.	Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US6162805A (en) *	1997-04-24	2000-12-19	Merck Sharp & Dohme Limited	Use of an NK-1 receptor antagonist and an SSRI for treating obesity
GB9923748D0 (en) *	1999-10-07	1999-12-08	Glaxo Group Ltd	Chemical compounds
MXPA02006017A (es) *	1999-12-17	2002-12-05	Schering Corp	Antagonistas de neuroquinina selectivos.
US6436928B1 (en) *	1999-12-17	2002-08-20	Schering Corporation	Selective neurokinin antagonists
GT200100147A (es) *	2000-07-31	2002-06-25		Derivados de imidazol
GB0025354D0 (en) *	2000-10-17	2000-11-29	Glaxo Group Ltd	Chemical compounds
GB0119797D0 (en) *	2001-08-14	2001-10-03	Glaxo Group Ltd	Chemical compounds
TW200300347A (en) *	2001-11-13	2003-06-01	Schering Corp	Nk1 antagonists
GB0203020D0 (en) *	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds

2003
- 2003-04-17 GB GBGB0308968.7A patent/GB0308968D0/en not_active Ceased
2004
- 2004-04-16 MX MXPA05011064A patent/MXPA05011064A/es unknown
- 2004-04-16 AU AU2004229181A patent/AU2004229181A1/en not_active Abandoned
- 2004-04-16 CA CA002522311A patent/CA2522311A1/fr not_active Abandoned
- 2004-04-16 US US10/552,982 patent/US20060287325A1/en not_active Abandoned
- 2004-04-16 KR KR1020057019520A patent/KR20060003875A/ko not_active Withdrawn
- 2004-04-16 EP EP04727895A patent/EP1613325A1/fr not_active Withdrawn
- 2004-04-16 JP JP2006505186A patent/JP2006523650A/ja active Pending
- 2004-04-16 US US10/552,870 patent/US20060241143A1/en not_active Abandoned
- 2004-04-16 JP JP2006505187A patent/JP2006523651A/ja active Pending
- 2004-04-16 RU RU2005135649/15A patent/RU2005135649A/ru not_active Application Discontinuation
- 2004-04-16 WO PCT/EP2004/004122 patent/WO2004091616A1/fr active Application Filing
- 2004-04-16 JP JP2006505185A patent/JP2006523649A/ja active Pending
- 2004-04-16 JP JP2006505188A patent/JP2006523652A/ja active Pending
- 2004-04-16 AU AU2004229179A patent/AU2004229179A1/en not_active Abandoned
- 2004-04-16 EP EP04739086A patent/EP1615642A1/fr not_active Withdrawn
- 2004-04-16 EP EP04739085A patent/EP1615641A1/fr not_active Withdrawn
- 2004-04-16 PL PL377857A patent/PL377857A1/pl not_active Application Discontinuation
- 2004-04-16 PL PL377858A patent/PL377858A1/pl not_active Application Discontinuation
- 2004-04-16 EP EP04727896A patent/EP1653956A1/fr not_active Withdrawn
- 2004-04-16 CN CNA2004800171620A patent/CN1809355A/zh active Pending
- 2004-04-16 RU RU2005135647/15A patent/RU2005135647A/ru not_active Application Discontinuation
- 2004-04-16 CN CNA2004800172252A patent/CN1809359A/zh active Pending
- 2004-04-16 MX MXPA05011063A patent/MXPA05011063A/es unknown
- 2004-04-16 WO PCT/EP2004/004121 patent/WO2004091615A1/fr active Application Filing
- 2004-04-16 WO PCT/EP2004/004126 patent/WO2004091624A1/fr active Application Filing
- 2004-04-16 BR BRPI0409377-1A patent/BRPI0409377A/pt not_active Application Discontinuation
- 2004-04-16 US US10/552,869 patent/US20060241124A1/en not_active Abandoned
- 2004-04-16 CA CA002522313A patent/CA2522313A1/fr not_active Abandoned
- 2004-04-16 BR BRPI0409379-8A patent/BRPI0409379A/pt not_active Application Discontinuation
- 2004-04-16 US US10/552,871 patent/US20060217395A1/en not_active Abandoned
- 2004-04-16 WO PCT/EP2004/004124 patent/WO2004091617A1/fr active Application Filing
- 2004-04-16 KR KR1020057019521A patent/KR20060003876A/ko not_active Withdrawn
2005
- 2005-10-06 ZA ZA200508067A patent/ZA200508067B/en unknown
- 2005-10-06 ZA ZA200508068A patent/ZA200508068B/en unknown
- 2005-10-14 CO CO05105292A patent/CO5700753A2/es not_active Application Discontinuation
- 2005-10-19 MA MA28561A patent/MA27730A1/fr unknown
- 2005-10-19 MA MA28562A patent/MA27731A1/fr unknown
- 2005-11-14 NO NO20055367A patent/NO20055367L/no not_active Application Discontinuation
- 2005-11-14 NO NO20055368A patent/NO20055368L/no not_active Application Discontinuation
- 2005-11-15 IS IS8129A patent/IS8129A/is unknown
- 2005-11-15 IS IS8128A patent/IS8128A/is unknown

Also Published As

Publication number	Publication date
KR20060003876A (ko)	2006-01-11
US20060241124A1 (en)	2006-10-26
EP1653956A1 (fr)	2006-05-10
CA2522313A1 (fr)	2004-10-28
CO5700753A2 (es)	2006-11-30
RU2005135647A (ru)	2006-06-10
WO2004091615A1 (fr)	2004-10-28
CN1809359A (zh)	2006-07-26
WO2004091624A1 (fr)	2004-10-28
RU2005135649A (ru)	2006-03-20
IS8128A (is)	2005-11-15
IS8129A (is)	2005-11-15
KR20060003875A (ko)	2006-01-11
BRPI0409377A (pt)	2006-04-25
WO2004091616A1 (fr)	2004-10-28
EP1615642A1 (fr)	2006-01-18
JP2006523650A (ja)	2006-10-19
WO2004091617A1 (fr)	2004-10-28
US20060241143A1 (en)	2006-10-26
US20060287325A1 (en)	2006-12-21
US20060217395A1 (en)	2006-09-28
JP2006523652A (ja)	2006-10-19
ZA200508068B (en)	2007-02-28
JP2006523649A (ja)	2006-10-19
EP1613325A1 (fr)	2006-01-11
MXPA05011064A (es)	2006-04-18
MA27731A1 (fr)	2006-01-02
PL377857A1 (pl)	2006-02-20
EP1615641A1 (fr)	2006-01-18
CA2522311A1 (fr)	2004-10-28
MXPA05011063A (es)	2005-12-12
JP2006523651A (ja)	2006-10-19
ZA200508067B (en)	2007-02-28
NO20055368L (no)	2005-11-14
MA27730A1 (fr)	2006-01-02
BRPI0409379A (pt)	2006-04-25
AU2004229179A1 (en)	2004-10-28
PL377858A1 (pl)	2006-02-20
CN1809355A (zh)	2006-07-26
GB0308968D0 (en)	2003-05-28
AU2004229181A1 (en)	2004-10-28

Legal Events

Date	Code	Title	Description
2007-11-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
JP2005532372A5 (fr)	2006-04-06
NO20081482L (no)	2008-05-16	Delta- og epsilon-krystallformer for imatinibmesylat
UA100364C2 (xx)	2012-12-25	Сукцинат біфеніл-2-ілкарбамінової кислоти 1-$2-(2-хлор-4-{$(r)-2-гідрокси-2-(8-гідроксі-2-оксо-1,2-дигідрохінолін-5-іл)етиламіно]метил]}-5-метоксифенілкарбамоїл)етил]піперидин-4-іл-естеру та його застосування для лікування легеневих розладів
EP1562897A4 (fr)	2007-06-27	Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
NO20045521L (no)	2004-12-17	Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
UY27993A1 (es)	2004-03-31	Derivados de 4-pirrolidino-fenil-bencil eter
NO20082477L (no)	2008-09-05	Krystallinske former av 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl-1-[(fosfonooksy)metyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioksoetyl]-piperazin
NO20074647L (no)	2007-11-09	3,4 dihydro-1H-isoquinolin-2-karboksylsyre-5-ammopyridin-2-yl estere
NO20073059L (no)	2007-07-19	2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
EA200400881A1 (ru)	2005-02-24	Азаарилпиперазины
NO20082498L (no)	2008-08-07	Diarylurea for behandling av pulmonar hypertensjon
NO20030724D0 (no)	2003-02-14	Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
NO20055367L (no)	2005-11-14	Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst
NO20076405L (no)	2008-02-11	Anvendelse av 24-nor-UDCA
BRPI0215703B8 (pt)	2021-05-25	polimorfo de ácido 4-[2-[1-(2-etoxietil)-1h-benzidimazol-2-il]-1-piperidinil]etil]-a, a-dimetil-benzenoacético, preparado farmacêutico, e seu uso do polimorfo 1
NO20060020L (no)	2006-03-03	3-fluorpiperidiner som NMDA/NR2B-antagonister
NO20065835L (no)	2007-02-16	Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander
NO20080133L (no)	2008-03-05	Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
BRPI0411324A (pt)	2006-07-25	composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
CY1112766T1 (el)	2016-02-10	Εγκαιρη χρηση ενος εκχυλισματος απο φυλλα κοκκινης ποικιλιας αμπελου
NO20091969L (no)	2009-05-20	N-(2-hydroksyetyl)-N-metyl-4-(quinolin-8-yl(1-(tiazol-4-ylmetyl)piperidin-4-yliden)metyl)benzamid, fremgangsmate for fremstilling av den sa vel som dens anvendelse for behandling av smerte, angst og depresjon
NO20052699L (no)	2005-06-06	4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
WO2004007441A3 (fr)	2004-04-08	Derives de 4,4' -dithiobis- (3-aminobutane-1-sulfonates) nouveaux et compositions les contenant
NO20060781L (no)	2006-03-17	Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
NO20054662L (no)	2005-12-05	Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre